No Data
No Data
Express News | Inozyme Pharma Inc : Raymond James Initiates Coverage With Outperform Rating; Target Price $26
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Here's Why Inozyme Pharma (INZY) Is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $14
No Data